NasdaqCM - Nasdaq Real Time Price USD

Evogene Ltd. (EVGN)

0.3667 -0.0079 (-2.11%)

As of 9:42:32 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

PR Newswire 5d ago

EVGN
-2.11%
Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

PR Newswire 7d ago

EVGN
-2.11%
Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

PR Newswire 13d ago

EVGN
-2.11%
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

PR Newswire 2mo ago

EVGN
-2.11%
Evogene (EVGN) Q2 2026 Earnings Call Transcript

Motley Fool 2mo ago

EVGN
-2.11%
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

PR Newswire 2mo ago

EVGN
-2.11%
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

PR Newswire 2mo ago

EVGN
-2.11%
Evogene and ELEO to develop new oral PCSK9 inhibitors

Pharmaceutical Technology 3mo ago

EVGN
-2.11%
Evogene Ltd. Q2 2026 Earnings Call Summary

Moby 2mo ago

NVDA

EVGN
-2.11%
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

PR Newswire 26d ago

EVGN
-2.11%
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

PR Newswire 1mo ago

EVGN
-2.11%
EverGen Infrastructure Reports Q2 2026 Results

Business Wire 2mo ago

EVGN.V

EVGN
-2.11%
EVGIF

Performance Overview

Return	EVGN	TA-125 (^TA125.TA)
YTD	-60.15%	+7.37%
1-Year	-70.27%	--
3-Year	-92.65%	+130.62%

U.S. markets close in 5h 35m

Evogene Ltd. (EVGN)

Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Evogene (EVGN) Q2 2026 Earnings Call Transcript

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene and ELEO to develop new oral PCSK9 inhibitors

Evogene Ltd. Q2 2026 Earnings Call Summary

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

EverGen Infrastructure Reports Q2 2026 Results